-
-
-
[1] Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment[J]. Genet Med, 2015, 17(1): 70-87. DOI:10.1038/gim.2014.147.
[2] Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention[J]. Fam Cancer, 2013, 12(2): 273-277. DOI:10.1007/s10689-013-9664-5.
[3] Wang YM, Xue FX, Broaddus RR, et al. Clinicopathological features in endometrial carcinoma associated with Lynch syndrome in China[J]. Int J Gynecol Cancer, 2009, 19(4): 651-656. DOI:10.1111/IGC.0b013e3181a12fb9.
[4] Helder-Woolderink JM, Blok EA, Vasen HF, et al. Ovarian cancer in Lynch syndrome; a systematic review[J]. Eur J Cancer, 2016, 55: 65-73. DOI:10.1016/j.ejca.2015.12.005.
[5] Niskakoski A, Kaur S, Renkonen-Sinisalo L, et al. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas[J]. Int J Cancer, 2013, 133(11): 2596-2608. DOI:10.1002/ijc.28287
[6] Boland PM, Yurgelun MB, Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes[J]. CA Cancer J Clin, 2018, 68(3): 217-231. DOI:10.3322/caac.21448.
[7] Kloor M, Staffa L, Ahadova A, et al. Clinical significance of microsatellite instability in colorectal cancer[J]. Langenbecks Arch Surg, 2014, 399(1): 23-31. DOI:10.1007/s00423-013-1112-3.
[8] Matsuo K, Machida H, Blake EA, et al. Trends and outcomes of women with synchronous endometrial and ovarian cancer[J]. Oncotarget, 2018, 9(47): 28757-28771. DOI:10.18632/oncotarget.25550.
[9] Niskakoski A, Pasanen A, Porkka N, et al. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: shared origin of synchronous carcinomas[J]. Gynecol Oncol, 2018, 150(1): 92-98. DOI:10.1016/j.ygyno.2018.04.566.
[10] Scully E, Young H. Metastatic Tumors of the Ovary. In: Kurman J eds. Blaustein's pathology of the female genital tract[M]. 3rd. New Yok: Springe, 1991: 742.
[11] Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895-2015[J]. Nat Rev Cancer, 2015, 15(3): 181-194. DOI:10.1038/nrc3878.
[12] Lynch HT, Lanspa S, Shaw T, et al. Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge[J]. Fam Cancer, 2018, 17(3): 403-414. DOI:10.1007/s10689-017-0053-3.
[13] Ten Broeke SW, van der Klift HM, Tops CMJ, et al. Cancer risks for PMS2-associated lynch syndrome[J]. J Clin Oncol, 2018, 36(29): 2961-2968. DOI:10.1200/JCO.2018.78.4777.
[14] Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability[J]. J Natl Cancer Inst, 2004, 96(4): 261-268. DOI:10.1093/jnci/djh034.
[15] Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5783-5788. DOI:10.1200/JCO.2008.17.5950.
[16] Rubenstein JH, Enns R, Heidelbaugh J, et al. American gastroenterological association institute guideline on the diagnosis and management of lynch syndrome[J]. Gastroenterology, 2015, 149(3): 777-782. DOI:10.1053/j.gastro.2015.07.036.
下载:
图(1)
计量
- 文章访问数: 403
- PDF下载数: 215
- 施引文献: 0